

#### New Methodologies for Chemical Risk Assessment

Course No: H02-012

Credit: 2 PDH

Gilbert Gedeon, P.E.



Continuing Education and Development, Inc.


P: (877) 322-5800 info@cedengineering.com



**ENVR 500** Environmental Processes, Exposure, and Risk Assessment:

# New Approach Methodologies for Chemical Risk Assessment

John Wambaugh Center for Computational Toxicology and Exposure Office of Research and Development U.S. Environmental Protection Agency



The views expressed in this presentation are those of the author and do not necessarily reflect the views or policies of the U.S. EPA



#### **US EPA Office of Research and Development**

- The Office of Research and Development (ORD) is the scientific research arm of EPA
  - 562 peer-reviewed journal articles in 2018
- Research is conducted by ORD's four national centers, and three offices organized to address:
  - Public health and env. assessment; comp. tox. and exposure; env. measurement and modeling; and env. solutions and emergency response.
- 13 facilities across the United States
- Research conducted by a combination of Federal scientists (including uniformed members of the Public Health Service); contract researchers; and postdoctoral, graduate student, and postbaccalaureate trainees





**ORD Facility in** Research Triangle Park, NC



#### **Chemical Regulation in the United States**

- Park et al. (2012): At least 3221 chemical signatures in pooled human blood samples, many appear to be exogenous
- A tapestry of laws covers the chemicals people are exposed to in the United States (Breyer, 2009)
- Different testing requirements exist for food additives, pharmaceuticals, and pesticide active ingredients (NRC, 2007)






#### **Chemical Regulation in the United States**

- Most other chemicals, ranging from industrial waste to dyes to packing materials, are covered by the Toxic Substances Control Act (TSCA)
- Thousands of chemicals on the market were "grandfathered" in without assessment Judson et al. (2009), Egeghy et al. (2012), Wetmore et al. (2015)


"Tens of thousands of chemicals are listed with the Environmental Protection Agency (EPA) for commercial use in the United States, with an average of 600 new chemicals listed each year."

U.S. Government Accountability Office






#### **Three Components for Chemical Risk**



NRC (1983)




The National Academy of Sciences, Engineering and Medicine (1983) outlined three components for determining chemical risk.



#### **Toxic Substances** Control Act (TSCA)

- TSCA was updated in June, 2016 to allow more rapid evaluation of chemicals (Frank R. Lautenberg Chemical Safety for the 21st Century Act)
- New approach methodologies (NAMs) are being considered to inform prioritization of chemicals for testing and evaluation (Kavlock et al., 2018)
- EPA has released a "A Working Approach for Identifying Potential Candidate Chemicals for Prioritization" (September, 2018)




Schmidt, C. W. (2016). TSCA 2.0: A new era in chemical risk management", Environmental Health Perspectives, A182-A186.



#### **Chemical Risk = Hazard x Exposure**

- The U.S. National Research Council (1983) identified chemical risk as a function of both inherent hazard and exposure
- To address thousands of chemicals, we need NAMs that can inform prioritization of chemicals most worthy of additional study
- High throughput risk prioritization needs:
  - 1. High throughput hazard characterization (Dix et al., 2007, Collins et al., 2008)
  - 2. High throughput exposure forecasts (Wambaugh et al., 2013, 2014)
  - 3. High throughput toxicokinetics (i.e., dose-response relationship) linking hazard and exposure (Wetmore et al., 2012, 2015)




## United States Environmental Protection Agency

# A VISION AND A STRATEGY

NRC (2007)

#### **High-Throughput Risk Prioritization**



To perform high throughput risk prioritization, we need all three components



#### High-throughput Screening

#### Hertzberg and Pope (2000):


"New technologies in high-throughput screening have significantly increased throughput and reduced assay volumes..."

**Positive** 

**Titration of** 


Kaewkhaw et al. (2016)

- "...new fluorescence methods, detection platforms and liquidhandling technologies."
- Typically assess many chemicals with a signal readout (e.g., green fluorescent protein).





#### The Margin Between Exposure and Hazard




- estimated or measured average concentrations associated with the LOAEL in animal studies
- NOAEL in animal studies
- Humans with chronic exposure reference values (solid circles)
- Volunteers using products containing the chemical
- Biomonitored occupational populations
- General populations



#### **High-Throughput Bioactivity Screening Projects**

- We attempt to estimate points of departure in vitro using high throughput screening (HTS)
- **Tox21**: Examining >8,000 chemicals using ~50 assays intended to identify interactions with biological pathways (Schmidt, 2009)
- ToxCast: For a subset (>2000) of Tox21 chemicals ran >1100 additional assays (Kavlock et al., 2012)
- Most assays conducted in dose-response format (identify 50% activity concentration –  $AC_{50}$  – and efficacy if data described by a Hill function, Filer et al., 2016)
- All data are public: http://comptox.epa.gov/dashboard/








### New Approach Methodologies (NAMs)

- There are roughly 10,000 TSCA-relevant chemicals in commerce
- Considering the inclusion of new approach methodologies (NAMs). These NAMs include:
  - High throughput screening (ToxCast)
  - High throughput exposure estimates (ExpoCast)
  - High throughput toxicokinetics (HTTK)



- TSCA Proof of concept: Examine ~200 chemicals with ToxCast, ExpoCast and HTTK
  - HTTK was rate limiter on number of chemicals
  - "A Proof-of-Concept Case Study Integrating Publicly Available Information to Screen Candidates for Chemical Prioritization under TSCA"



#### Replacing Animal Testing with NAMs

- "To aggressively pursue a reduction in animal testing, I am directing leadership and staff in the Office of Chemical Safety and Pollution Prevention and the Office of Research and Development [ORD] to prioritize ... the reduction of animal testing while ensuring protection of human health and the environment."
- "These new approach methods (NAMs), include any technologies, methodologies, approaches or combinations thereof that can be used to provide information on chemical hazard and potential human exposure that can avoid or significantly reduce the use of testing on animals"
  - NAMs for filling information gaps for decision-making
  - integrating data steams into chemical risk assessment
  - making the information publicly available



#### September 10, 2019

HE ADMINISTRATOR

#### MEMORANDUM

SUBJECT: Directive to Prioritize Efforts to Reduce Animal Testing

FROM: Andrew R. Wheeler

Administrator

TO: Associate Deputy Administrator

General Counsel

Assistant Administrators Inspector General

Chief Financial Officer

Chief of Staff

Associate Administrators

Regional Administrators

During my March 2019 all-hands address, I reiterated the U.S. Environmental Protection Agency's commitment to move away from animal testing. We are already making significant efforts to reduce, replace and refine our animal testing requirements under both statutory and strategic directives. For example, the Toxic Substances Control Act, amended June 22, 2016, by the Frank R. Lautenberg Chemical Safety for the 21st Century Act, requires the EPA to reduce reliance on animal testing. Also, Objective 3.3 of the FY 2018-2022 U.S. EPA Strategic Plan outlines a commitment to further reduce the reliance on animal testing within five years. More than 200,000 laboratory animals have been saved in recent years as a result of these collective efforts.

Scientific advancements exist today that allow us to better predict potential hazards for risk assessment purposes without the use of traditional methods that rely on animal testing. These new approach methods (NAMs), include any technologies, methodologies, approaches or combinations thereof that can be used to provide information on chemical hazard and potential human exposure that can avoid or significantly reduce the use of testing on animals. The benefits of NAMs are extensive, not only allowing us to decrease animals used while potentially evaluating more chemicals across a broader range of potential biological effects, but in a shorter timeframe with fewer resources while often achieving equal or greater biological predictivity than current animal models.



#### We Still Need Toxicokinetics and Exposure


The National Academies of SCIENCES · ENGINEERING · MEDICINE USING 21ST CENTURY SCIENCE TO IMPROVE RISK-RELATED **EVALUATIONS** NASEM (2017)

Hazard **High-Throughput** Risk **Prioritization Toxicokinetics Exposure** 

"Translation of high-throughput data into riskbased rankings is an important application of exposure data for chemical priority-setting. Recent advances in high-throughput toxicity assessment, notably the ToxCast and Tox21 programs... and in highthroughput computational exposure assessment [ExpoCast] have enabled first-tier risk-based rankings of chemicals on the basis of margins of exposure" - National Academies of Sciences, Engineering, and Medicine (NASEM)




#### **Chemical Prioritization NAMs**



High throughput in vitro screening can estimate doses needed to cause bioactivity (e.g., Wetmore et al., 2015)

Exposure intake rates can be inferred from biomarkers (e.g., Ring et al., 2018)




Estimated Equivalent Dose or Predicted Exposure



## In Vitro - In Vivo Extrapolation (IVIVE)

IVIVE is the use of *in vitro* experimental data to predict phenomena *in vivo* 


- IVIVE-PK/TK (**Pharmacokinetics/Toxicokinetics**):
  - Fate of molecules/chemicals in body
  - Considers absorption, distribution, metabolism, excretion (ADME)
  - Uses empirical PK and physiologically-based (PBPK) modeling
- IVIVE-PD/TD (**Pharmacodynamics/Toxicodynamics**):
  - Effect of molecules/chemicals at biological target in vivo
  - Assay design/selection important
  - Perturbation as adverse/therapeutic effect, reversible/irreversible effects
- Both contribute to *in vivo* effect prediction





#### High Throughput Toxicokinetics (HTTK)


## In vitro toxicokinetic data + generic toxicokinetic model = high(er) throughput toxicokinetics






## In Vitro Data for HTTK

Cryopreserved hepatocyte suspension Shibata et al. (2002)



The rate of disappearance of parent compound (slope of line) is the hepatic clearance  $(\mu L/min/10^6)$ hepatocytes)




We perform the assay at 1 and 10 µM to check for saturation of metabolizing enzymes.

- Most chemicals do not have TK data we use *in vitro* HTTK methods adapted from pharma to fill gaps
- In drug development, HTTK methods allow **IVIVE** to estimate therapeutic doses for clinical studies predicted concentrations are typically on the order of values measured in clinical trials (Wang, 2010)



## In Vitro Data for HTTK

Cryopreserved hepatocyte suspension Shibata et al. (2002)



Cryopreserved **Hepatocytes** (10 donor pool)

**Add Chemical**  $(1 \text{ and } 10 \mu M)$ 

Remove Aliquots at 15, 30, 60, 120 min

**Analytical** Chemistry

Rapid Equilibrium Dialysis (RED) Waters et al.

(2008)

**Double-wells** connected by semi-permeable membrane on a **RED Plate** 

Add plasma (6 donor pool) to one well

Add chemical

$$F_{ub,p} = \frac{C_{well1}}{C_{well2}}$$

**Incubate** plates come to equilibrium **Determine** (analytical chemistry)

- Most chemicals do not have TK data we use *in vitro* HTTK methods adapted from pharma to fill gaps
- HTTK methods allow **IVIVE** to estimate therapeutic doses for clinical studies predicted concentrations are **concentration** typically on the order in both wells of values measured in clinical trials (Wang, 2010)

In drug development,



## In Vitro Data for HTTK

Cryopreserved hepatocyte suspension Shibata et al. (2002)









**Add Chemical** 

 $(1 \text{ and } 10 \mu M)$ 







Cryopreserved **Hepatocytes** (10 donor pool)



Remove Aliquots at 15, 30, 60, 120 min











**Determine** 

concentration

in both wells

(analytical

chemistry)

Environmental chemicals:

gaps

Rotroff et al. (2010) 35 chemicals

Wetmore et al. (2012)

+204 chemicals

Most chemicals do

not have TK data –

methods adapted

from pharma to fill

we use *in vitro* HTTK

Wetmore et al. (2015)

+163 chemicals

Wambaugh et al. (2019) +389 chemicals

Rapid Equilibrium Dialysis (RED) Waters et al. (2008)

**Double-wells** connected by semi-permeable membrane on a **RED Plate** 

Add plasma (6 donor pool) to one well


**Add chemical** 

**Incubate** plates come to equilibrium

20 of 53 Office of Research and Development




- To evaluate a **chemical-specific TK model** for "chemical x" you can compare the predictions to in vivo measured data
  - Can estimate bias
  - Can estimate uncertainty
  - Can consider using model to extrapolate to other situations (dose, route, physiology) where you don't have data







- To evaluate a **chemical-specific TK model** for "chemical x" you can compare the predictions to in vivo measured data
  - Can estimate bias
  - Can estimate uncertainty
  - Can consider using model to extrapolate to other situations (dose, route, physiology) where you don't have data
- However, we do not typically have TK data






- To evaluate a **chemical-specific TK model** for "chemical x" you can compare the predictions to in vivo measured data
  - Can estimate bias
  - Can estimate uncertainty
  - Can consider using model to extrapolate to other situations (dose, route, physiology) where you don't have data
- However, we do not typically have TK data
- We can parameterize a **generic TK model**, and evaluate that model for as many chemicals as we do have data
  - We do expect larger uncertainty, but also greater confidence in model implementation
  - Estimate bias and uncertainty, and try to correlate with chemical-specific properties








- To evaluate a **chemical-specific TK model** for "chemical x" you can compare the predictions to in vivo measured data
  - Can estimate bias
  - Can estimate uncertainty
  - Can consider using model to extrapolate to other situations (dose, route, physiology) where you don't have data
- However, we do not typically have TK data
- We can parameterize a **generic TK model**, and evaluate that model for as many chemicals as we do have data
  - We do expect larger uncertainty, but also greater confidence in model implementation
  - Estimate bias and uncertainty, and try to correlate with chemical-specific properties
  - Can consider using model to extrapolate to other situations (chemicals without in vivo data)







**Predicted Concentrations** 



- To evaluate a **chemical-specific TK model** for "chemical x" you can compare the predictions to in vivo measured data
  - Can estimate bias
  - Can estimate uncertainty
  - Can consider using model to extrapolate to other situations (dose, route, physiology) where you don't have data
- However, we do not typically have TK data
- We can parameterize a **generic TK model**, and evaluate that model for as many chemicals as we do have data
  - We do expect larger uncertainty, but also greater confidence in model implementation
  - Estimate bias and uncertainty, and try to correlate with chemical-specific properties
  - Can consider using model to extrapolate to other situations (chemicals without in vivo data)








- We estimate clearance from two processes – hepatic metabolism (liver) and passive glomerular filtration (kidney)
- This appears to work better for pharmaceuticals than other chemicals:
  - ToxCast chemicals are overestimated
- Non-pharmaceuticals may be subject to extrahepatic metabolism and/or active transport


#### **Evaluation Example**





#### Toxicokinetic Triage: When Does TK IVIVE

- Through comparison to in vivo data, a crossvalidated (random forest) predictor of success or failure of HTTK has been constructed
- All chemicals can be placed into one of seven confidence categories
  - Added categories for chemicals that do not reach steady-state or for which plasma binding assay fails
- Plurality of chemicals end up in the "on the order" bin (within a factor of 3.2x) which is consistent with Wang (2010)






Different crayons have different colors...

Until I open the box, I don't know what colors I have...

...especially if my six-year-old has been around.

### **Uncertainty**





Different crayons have different colors...

The "average" color may not even be in the box!


#### **Variability**





Different crayons have different colors...

The "average" color may not even be in the box!



#### **Variability**





Correlated Monte Carlo sampling of physiological model parameters built into R "httk" package (Pearce et al., 2017):

# Sample NHANES biometrics for actual individuals:

Sex

Race/ethnicity

Age

Height

Weight

Serum creatinine

#### **Population simulator for HTTK**





**Correlated Monte Carlo** sampling of physiological model parameters built into R "httk" package (Pearce et al., 2017):

Sample NHANES biometrics for actual individuals:

Sex

Race/ethnicity

Age

Height

Weight

Serum creatinine

#### **Population simulator for HTTK**



Regression equations from literature (McNally *et al.*, 2014) (+ residual marginal variability)

(Similar approach used in SimCYP [Jamei et al. 2009], GastroPlus, PopGen [McNally et al. 2014], P3M [Price et al. 2003], physB [Bosgra et al. 2012], etc.)

Slide from Caroline Ring (ToxStrategies)



**Correlated Monte Carlo** sampling of physiological model parameters built into R "httk" package (Pearce et al., 2017):

Sample NHANES biometrics for actual individuals:

Sex

Race/ethnicity

Age

Height

Weight

Serum creatinine

#### **Population simulator for HTTK**



**Predict** physiological quantities

Tissue masses Tissue blood flows GFR (kidney function) Hepatocellularity


Regression equations from literature (McNally *et al.*, 2014) (+ residual marginal variability)

(Similar approach used in SimCYP [Jamei et al. 2009], GastroPlus, PopGen [McNally et al. 2014], P3M [Price et al. 2003], physB [Bosgra et al. 2012], etc.)

Slide from Caroline Ring (ToxStrategies)




#### **Risk-Based Ranking for Total NHANES Population**






#### Life-stage and Demographic Variation in Exposure

• Wambaugh et al. (2014) made steadystate inferences of exposure rate (mg/kg/day) from NHANES data for various demographic groups




Change in Exposure Relative to Total Population






### Life-stage and Demographic Variation in TK

• Ring et al. (2017) made demographicspecific predictions of change in plasma concentrations for a 1 mg/kg bw/day exposure




Change in Toxicokinetics Relative to Total Population







### Life-stage and Demographic Variation in Risk Priority

 Can calculate margin between bioactivity and exposure for specific populations






Change in Risk Relative to **Total Population** 





### **Open Source Tools and Data for HTTK**

https://CRAN.R-project.org/package=httk



ggplot2, knitr, rmarkdown, R.rsp, GGally, gplots, scales, EnvStats, MASS, RColorBrewer, TeachingDer Suggests:

emodels, colorspace

Published: 2019-09-10

John Wambaugh [aut, cre], Robert Pearce [aut], Caroline Ring [aut], Greg Honda [aut], Mark Sfeir [aut] Author:

Wetmore [ctb], Woodrow Setzer [ctb]

John Wambaugh <wambaugh.john at epa.gov> Maintainer: BugReports: https://github.com/USEPA/CompTox-ExpoCast-httk

License: GPL-3

https://www.epa.gov/chemical-research/rapid-chemical-exposure-and-dose-research URL:

NeedsCompilation: yes Materials: NEWS CRAN checks: httk results

downloads 474/month

Downloads:

Reference manual: httk.pdf

Honda et al. (2019): Updated Armitage et al. (2014) Model Vignettes:

Pearce et al. (2017) Creating Partition Coefficient Evaluation Plots

Ring et al. (2017) Age distributions

Ring et al. (2017) Global sensitivity analysis

Ring et al. (2017) Global sensitivity analysis plotting


Ring et al. (2017) Height and weight spline fits and residuals

# R package "httk"

- Open source, transparent, and peerreviewed tools and data for high throughput toxicokinetics (httk)
- Available publicly for free statistical software
- Allows in vitro-in vivo extrapolation (IVIVE) and physiologically-based toxicokinetics (PBTK)
- Human-specific data for 944 chemicals and rat-specific data for 171 chemicals



Risk = Hazard x Exposure





# Risk = Hazard x Exposure

High throughput screening (Dix et al., 2006, Collins et al., 2008) + in vitro-in vivo extrapolation (IVIVE, Wetmore et al., 2012, 2015) can predict a dose (mg/kg bw/day) that might be adverse

Need methods to forecast exposure for thousands of chemicals (Wetmore et al., 2015) Hazard High throughput models exist to make predictions of exposure via

**Prioritization** 

**High-Throughput** 

Risk

**Toxicokinetics** 

**Exposure** 


specific, important pathways such


as residential product use and diet



### Limited Available Data for Exposure **Estimation**

Most chemicals lack public exposure-related data beyond production volume (Egeghy et al., 2012)





- **Exposure event unobservable:** Can try to predict exposure by characterizing pathway
- Some pathways have much higher average exposures: In home "Near field" sources significant (Wallace, et al., 1987)



### New Approach Methodologies for Exposure Science

			Makes Use of					
<b>Exposure NAM Class</b>	Description	Traditional Approach	Measurement	Toxicokinetics	Models	Descriptors	Evaluation	Machine Learning
Measurements	New techniques including screening analyses capable of detecting hundreds of chemicals present in a sample	Targeted (chemical-specific) analyses	-	•	•	•		•
Toxicokinetics	High throughput methods using in vitro data to generate chemical-specific models	Analyses based on in vivo animal studies	•	-		•		•
HTE Models	Models capable of making predictions for thousands of chemicals	Models requiring detailed, chemical- and scenario-specific information	•	•	-	•		
Chemical Descriptors	Informatic approaches for organizing chemical information in a machine-readable format	Tools targeted at single chemical analyses by humans				-		•
Evaluation	Statistical approaches that use the data from many chemicals to estimate the uncertainty in a prediction for a new chemical	Comparison of model predictions to data on a per chemical basis	•	•	•	•	-	•
Machine Learning	Computer algorithms to identify patterns	Manual Inspection of the Data	•	•		•		-
Prioritization	Integration of exposure and other NAMs to identify chemicals for follow-up study	Expert decision making	•	•	•	•	•	•



# What Do We Know About Exposure? **Biomonitoring Data**

- Centers for Disease Control and Prevention (CDC) National Health and Nutrition Examination Survey (NHANES) provides an important tool for monitoring public health
- Large, ongoing CDC survey of US population: demographic, body measures, medical exam, biomonitoring (health and exposure), ...
- Designed to be representative of US population according to census data
- Data sets publicly available (http://www.cdc.gov/nchs/nhanes.htm)
- Includes measurements of:
  - Body weight
  - Height
  - Chemical analysis of blood and urine





# What Do We Know About Exposure? **Exposure Models**

- Human chemical exposures can be coarsely grouped into "near field" sources that are close to the exposed individual (consumer or occupational exposures) 'far-field' scenarios wherein individuals are exposed to chemicals that were released or used far away (ambient exposure) (Arnot et al., 2006).
- A model captures knowledge and a hypothesis of how the world works (MacLeod et al., 2010)
- EPA's EXPOsure toolBOX (EPA ExpoBox) is a toolbox created to assist individuals from within government, industry, academia, and the general public with assessing exposure
  - Includes many, many models https://www.epa.gov/expobox


"Now it would be very remarkable if any system existing in the real world could be exactly represented by any simple model. However, cunningly chosen parsimonious models often do provide remarkably useful approximations... The only question of interest is 'Is the model illuminating and useful?'" George Box



### **Evaluation NAMs: The SEEM Framework**


We use Bayesian methods to incorporate multiple models into consensus predictions for 1000s of chemicals within the Systematic Empirical Evaluation of Models (SEEM)

(Wambaugh et al., 2013, 2014; Ring et al., 2018)





# **Heuristics of Exposure**



 $R^2 \approx 0.5$  indicates that we can predict 50% of the chemical to chemical variability in median NHANES exposure rates


Same five predictors work for all NHANES demographic groups analyzed – stratified by age, sex, and body-mass index:

- Industrial and Consumer use
- Pesticide Inert
- Pesticide Active
- Industrial but no Consumer use
- **Production Volume**



### **Correlation is Not Causation**

- Wambaugh et al. (2014) found that "pesticide inerts" had higher than average levels in biomonitoring data, while "pesticide actives" had lower than average
- In World War II, there Royal Air Force (UK) wanted to armor planes against anti-aircraft fire
  - Initial proposal was to place armor wherever bullet holes were most common
  - Mathematician Abraham Wald pointed out that they were looking at the planes that had returned
  - See Drum, Kevin (2010) "The Counterintuitive World"
- Pesticide inerts have many other uses, but there are more stringent reporting requirements for pesticides
  - **Exposure is occuring by other pathways**





# **Knowledge of Exposure Pathways Limits** High Throughput Exposure Models

"In particular, the assumption that 100% of [quantity emitted, applied, or ingested] is being applied to each individual use scenario is a very conservative assumption for many compound / use scenario pairs."



This is an open access article published under an ACS AuthorChoice <u>License</u>, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.




pubs.acs.org/est

Risk-Based High-Throughput Chemical Screening and Prioritization using Exposure Models and in Vitro Bioactivity Assays

Hyeong-Moo Shin,\*,† Alexi Ernstoff,‡,§ Jon A. Arnot, Barbara A. Wetmore, Susan A. Csiszar,§ Peter Fantke,<sup>‡</sup> Xianming Zhang,<sup>○</sup> Thomas E. McKone, <sup>♠,¶</sup> Olivier Jolliet,<sup>§</sup> and Deborah H. Bennett<sup>†</sup>



### Chemical Use Identifies Relevant Pathways



Near field sources have been known to be important at least since 1987 – see Wallace, et al.



# **Chemical Property NAMs**

**Environmental Protection** 



Contents lists available at ScienceDirect

#### Food and Chemical Toxicology

journal homepage: www.elsevier.com/locate/foodchemtox



Occurrence and quantitative chemical composition

### SCIENTIFIC DATA (1011) O (11011) O (

Data Descriptor: The Chemical and Products Database, a resource for exposure-relevant data on chemicals in consumer products

Received: 16 October 2017

Kathie L. Dionisio1, Katherine Phillips1, Paul S. Price1, Christopher M. Grulke2, Antony Williams<sup>2</sup>, Derya Biryol<sup>1,3</sup>, Tao Hong<sup>4</sup> & Kristin K. Isaacs<sup>1</sup>

Development of a consumer product ingredient database for chemical exposure screening and prioritization

M.-R. Goldsmith a,\*, C.M. Grulke a, R.D. Brooks b, T.R. Transue C, Y.M. Tan A, A. Frame a,C, P.P. Egeghy a, R. Edwards d, D.T. Chang a, R. Tornero-Velez A, K. Isaacs A, A. Wang A, J. Johnson K, K. Holm A, M. Reich L, I. Mitchell g. D.A. Vallero a. L. Phillips a. M. Phillips a. I.F. Wambaugh a. R.S. Judson a. T.J. Buckley a, C.C. Dary

#### Broad "index" of chemical uses



Contents lists available at ScienceDirect

#### **Toxicology Reports**

journal homepage: www.elsevier.com/locate/toxrep



**CPCat** 



Exploring consumer exposure pathways and patterns of use for chemicals in the environment





**Ingredient** Lists

Occurrence data

Measured Data

**Green Chemistry** PAPER High-throughput screening of chemicals as CrossMark functional substitutes using structure-based Cite this: Green Chem., 2017, 19, classification models† Katherine A. Phillips, \*a.c John F. Wambaugh, b Christopher M. Grulke, b Kathie L. Dionisio<sup>c</sup> and Kristin K. Isaacs<sup>c</sup>

**Functional Use Data** 

The roles that chemicals serve in products



Cite This: Environ. Sci. Technol. 2018, 52, 3125-3135

pubs.acs.org/est

#### Suspect Screening Analysis of Chemicals in Consumer Products

Katherine A. Phillips, \* Alice Yau, \* Kristin A. Favela, \* Kristin K. Isaacs, \* Andrew McEachran, \* I Christopher Grulke, Ann M. Richard, Antony J. Williams, Jon R. Sobus, Russell S. Thomas, and John F. Wambaugh\*

Measurement of chemicals in consumer products

Journal of Exposure Science and Environmental Epidemiology (2018) 28, 216-222 © 2018 Nature America, Inc., part of Springer Nature. All rights reserved 1559-0631/18

#### **ORIGINAL ARTICLE**

Consumer product chemical weight fractions from ingredient lists

Kristin K. Isaacs<sup>1</sup>, Katherine A. Phillips<sup>1</sup>, Derya Biryol<sup>1,2</sup>, Kathie L. Dionisio<sup>1</sup> and Paul S. Price<sup>1</sup>

51 of 53 Office of Research and Development

https://comptox.epa.gov/dashboard



# What is "High Throughput"?

- Tox21: Testing one assay across 10,000 chemicals takes 1-2 days, but only 50 assays have been developed so far that can run that fast
- ToxCast: ~1100 off-the-shelf (pharma) assay-endpoints tested for up to 4,000 chemicals over the past decade, now developing new assays as well

HTS tox assays often use single readout, such as fluorescence, across many chemicals, measuring concentration for toxicokinetics or exposure requires chemical-specific methods...


- ExpoCast: Ring et al. made in silico predictions for ~480,000 chemicals from structure, but based on NHANES monitoring for ~120 chemicals
  - Quantitative non-targeted analysis (NTA) may eventually provide greater evaluation data to reduce uncertainty
- HTTK: In vitro data on 944 chemicals collected for humans, starting with Rotroff et al. (2010)
  - Work continues to develop *in silico* tools, e.g. Sipes et al. (2016)

Our work is not done...



# Summary

- A tapestry of laws covers the chemicals people are exposed to in the United States (Breyer, 2009)
- Most other chemicals, ranging from industrial waste to dyes to packing materials, are covered by the recently updated Toxic Substances Control Act (TSCA) and administered by the EPA
- New approach methodologies (NAMs) are being developed to prioritize these existing and new chemicals for testing
- All data are being made public:
  - The CompTox Chemicals Dashboard (A search engine for chemicals) <a href="http://comptox.epa.gov/">http://comptox.epa.gov/</a>
  - R package "httk": <a href="https://CRAN.R-project.org/package=httk">https://CRAN.R-project.org/package=httk</a>



The views expressed in this presentation are those of the authors and do not necessarily reflect the views or policies of the U.S. EPA

# ExpoCast Project (Exposure Forecasting)

#### **NCCT**

Chris Grulke
Richard Judson

Ann Richard

Risa Sayre\*

Mark Sfeir\*

**Rusty Thomas** 

John Wambaugh

**Antony Williams** 

#### **NRMRL**

Xiaoyu Liu

#### NHEERL

Linda Adams

Christopher

Ecklund

Marina Evans

Mike Hughes

Jane Ellen

Simmons

Tamara Tal

#### **NERL**

Cody Addington\*

Namdi Brandon\*

Alex Chao\*

#### **Kathie Dionisio**

**Peter Egeghy** 

Hongtai Huang\*

#### **Kristin Isaacs**

Ashley Jackson\*

Jen Korol-Bexell\*

Anna Kreutz\*

Charles Lowe\*

Seth Newton

\*Trainees

### Katherine Phillips

Paul Price

Jeanette Reyes\*

Randolph Singh\*

Marci Smeltz

Jon Sobus

John Streicher\*

Mark Strynar

Mike Tornero-Velez

Elin Ulrich

Dan Vallero

Barbara Wetmore

### Collaborators

**Arnot Research and Consulting** 

Jon Arnot

Johnny Westgate

Institut National de l'Environnement et des Risques (INERIS)

(IIVENIS)

Frederic Bois

**Integrated Laboratory Systems** 

Kamel Mansouri

**National Toxicology Program** 

Mike Devito

Steve Ferguson

Nisha Sipes

Ramboll

Harvey Clewell

ScitoVation

**Chantel Nicolas** 

**Silent Spring Institute** 

**Robin Dodson** 

**Southwest Research Institute** 

Alice Yau

Kristin Favela

**Summit Toxicology** 

Lesa Aylward

**Technical University of Denmark** 

Peter Fantke

**Tox Strategies** 

Caroline Ring

Miyoung Yoon

Unilever

**Beate Nicol** 

Cecilie Rendal

Ian Sorrell

**United States Air Force** 

Heather Pangburn

**Matt Linakis** 

**University of California, Davis** 

**Deborah Bennett** 

**University of Michigan** 

Olivier Jolliet

**University of Texas, Arlington** 

Hyeong-Moo Shin



### References

- Cohen Hubal, EA, et al. "Advancing internal exposure and physiologically-based toxicokinetic modeling for 21stcentury risk assessments." Journal of exposure science & environmental epidemiology (2018).
- Eissing, Thomas, et al. "A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks." Frontiers in physiology 2 (2011): 4.
- Frank, Christopher L., et al. "Defining toxicological tipping points in neuronal network development." Toxicology and applied pharmacology 354 (2018): 81-93.
- Honda, Gregory S., et al. "Using the concordance of in vitro and in vivo data to evaluate extrapolation assumptions." PloS one 14.5 (2019): e0217564.
- Jamei, et al. "The Simcyp® population-based ADME simulator." Expert opinion on drug metabolism & toxicology 2009b;5:211-223
- Jongeneelen, Frans J., and Wil F. Ten Berge. "A generic, cross-chemical predictive PBTK model with multiple entry routes running as application in MS Excel; design of the model and comparison of predictions with experimental results." Annals of occupational hygiene 55.8 (2011): 841-864.

- Breyer, Stephen. Breaking the vicious circle: Toward effective risk regulation. Harvard University Press, 2009
- Collins FS, Gray GM, Bucher JR. Transforming environmental health protection. Science. 2008;319:906– 907. [PMC free article] [PubMed]
- Dix David, et al. "The ToxCast program for prioritizing toxicity testing of environmental chemicals." Toxicol Sci. 2007;95:5–12
- Egeghy, P. P., et al. (2012). The exposure data landscape for manufactured chemicals. Science of the Total Environment, 414, 159-166.
- Judson, Richard S., et al. "In vitro screening of environmental chemicals for targeted testing prioritization: the ToxCast project." Environmental health perspectives 118.4 (2009): 485-492.
- Kavlock, R. J., et al. (2018). Accelerating the pace of chemical risk assessment. Chemical research in toxicology, 31(5), 287-290.
- Mansouri, Kamel, et al. "OPERA models for predicting physicochemical properties and environmental fate endpoints." Journal of cheminformatics 10.1 (2018): 10.
- McLanahan, Eva D., et al. "Physiologically based pharmacokinetic model use in risk assessment—why being published is not enough." Toxicological Sciences 126.1 (2011): 5-15.

- effective risk regulation. Harvard University Press, 2009
- Egeghy, P. P., et al. (2012). The exposure data landscape for manufactured chemicals. Science of the Total Environment, 414, 159-166.
- Filer, Dayne L.. "The ToxCast analysis pipeline: An R package for processing and modeling chemical screening data." US Environmental Protection Agency: http://www.epa. gov/ncct/toxcast/files/MySQL% 20Database/Pipeline\_Overview.pdf (2014)
- Hertzberg, R. P., & Pope, A. J. (2000). High-throughput screening: new technology for the 21st century. Current opinion in chemical biology, 4(4), 445-451.
- Ingle, Brandall L., et al. "Informing the Human Plasma Protein Binding of Environmental Chemicals by Machine Learning in the Pharmaceutical Space: Applicability Domain and Limits of Predictability." Journal of Chemical Information and Modeling 56.11 (2016): 2243-2252.
- Jamei, et al. "The Simcyp® population-based ADME simulator." Expert opinion on drug metabolism & toxicology 2009;5:211-223
- Kaewkhaw, R., et al. (2016). Treatment paradigms for retinal and macular diseases using 3-D retina cultures derived from human reporter pluripotent stem cell linestreatment design using PSC-Derived 3-D retina cultures. Investigative ophthalmology & visual science, 57(5), ORSFI1-ORSFI11.
- Kavlock, Robert, et al. "Update on EPA's ToxCast program: providing high throughput decision support tools for chemical risk management." Chemical research in

Office of Research and Development

Lukacova, Viera, Walter S. Woltosz, and Michael B. Bolger.